21 October 2015

NICE, Level 1, City Tower, Piccadilly Plaza, Manchester

The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00

 Please note that this agenda is subject to change prior to the meeting.

Final Agenda

1. Welcome and introduction to format of meeting - Part 1 only (open session)

2. Apologies - Part 1 only (open session)

3. Any other business - Part 1 only (open session)

4. Minutes from the last meeting held on 17 September 2015 - Part 1 only (open session)

5. Evaluation of Elosulfase alfa for treating mucopolysaccharidosis type IVA

5.1. Declarations of interest - Part 1 only (open session)

5.2. Introduction by the Chair, Dr Peter Jackson - Part 1 only (open session)

5.3. Presentation by the Chair, Dr Peter Jackson - Part 1 and Part 2 (open and closed session)

5.4. Agreement on the content of the Evaluation Consultation Document (ECD) or Final Evaluation Determination (FED) - Part 2 only (closed session)

6.  Evaluation of Asfotase alfa for treating paediatric-onset hypophosphatasia 

6.1. Declarations of interest - Part 1 only (open session)

6.2. Introduction by the Chair, Dr Peter Jackson - Part 1 only (open session)

6.3. Presentation by the Lead team, Dr Trevor Cole, Jeremy Manuel and Francis Pang - Part 1 and Part 2 (open and closed session)

6.4. Agreement on the content of the Evaluation Consultation Document (ECD) or Final Evaluation Determination (FED) - Part 2 only (closed session)

Date, time and venue of next meeting

Tuesday 17 November 2015 10:00am, NICE, Level 1, City Tower, Piccadilly Plaza, Manchester, M1 4BT.

 Please note all timings are approximate.

To print this agenda, please right click and select ‘Print’ from the menu

 

 

Registration period: 24 September 2015 to 07 October 2015
Registration is closed.